KR20050056235A - (2-이미다졸린-2-일아미노)퀴녹살린을 사용하여 치매 및파킨슨병을 처치하는 방법 - Google Patents

(2-이미다졸린-2-일아미노)퀴녹살린을 사용하여 치매 및파킨슨병을 처치하는 방법 Download PDF

Info

Publication number
KR20050056235A
KR20050056235A KR1020057006115A KR20057006115A KR20050056235A KR 20050056235 A KR20050056235 A KR 20050056235A KR 1020057006115 A KR1020057006115 A KR 1020057006115A KR 20057006115 A KR20057006115 A KR 20057006115A KR 20050056235 A KR20050056235 A KR 20050056235A
Authority
KR
South Korea
Prior art keywords
neurons
alpha
apoptosis
brimonidine
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057006115A
Other languages
English (en)
Korean (ko)
Inventor
윌리암 지. 타톤
래리 에이. 휠러
다니엘 더블유. 길
존 이. 도넬로
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Publication of KR20050056235A publication Critical patent/KR20050056235A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020057006115A 2002-10-08 2003-10-07 (2-이미다졸린-2-일아미노)퀴녹살린을 사용하여 치매 및파킨슨병을 처치하는 방법 Ceased KR20050056235A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41703102P 2002-10-08 2002-10-08
US60/417,031 2002-10-08

Publications (1)

Publication Number Publication Date
KR20050056235A true KR20050056235A (ko) 2005-06-14

Family

ID=32093952

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057006115A Ceased KR20050056235A (ko) 2002-10-08 2003-10-07 (2-이미다졸린-2-일아미노)퀴녹살린을 사용하여 치매 및파킨슨병을 처치하는 방법

Country Status (20)

Country Link
US (1) US20040116436A1 (enExample)
EP (1) EP1549314B1 (enExample)
JP (1) JP2006504741A (enExample)
KR (1) KR20050056235A (enExample)
CN (1) CN100370988C (enExample)
AT (1) ATE380551T1 (enExample)
AU (2) AU2003279874A1 (enExample)
BR (1) BR0314541A (enExample)
CA (1) CA2501348A1 (enExample)
DE (1) DE60318081T2 (enExample)
ES (1) ES2297233T3 (enExample)
HK (1) HK1080408B (enExample)
IL (1) IL167848A (enExample)
MX (1) MXPA05003665A (enExample)
NO (1) NO20051664L (enExample)
NZ (1) NZ539329A (enExample)
PL (1) PL376347A1 (enExample)
RU (1) RU2332218C2 (enExample)
WO (1) WO2004032934A1 (enExample)
ZA (1) ZA200502745B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares
DE102009043750A1 (de) * 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
US10022341B2 (en) * 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
RU2680526C1 (ru) * 2016-07-05 2019-02-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота
CA3031528A1 (en) * 2016-08-01 2018-02-08 Cognoptix, Inc. System and method for detecting tau protein in ocular tissue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
WO1996037226A2 (en) * 1995-05-26 1996-11-28 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective nmda antagonists
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
IL136388A0 (en) * 1997-12-04 2001-06-14 Allergan Sales Inc Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
CN100569291C (zh) * 2000-07-14 2009-12-16 阿勒根公司 含有α-2肾上腺素能激动剂的组合物

Also Published As

Publication number Publication date
EP1549314B1 (en) 2007-12-12
IL167848A (en) 2010-11-30
CN100370988C (zh) 2008-02-27
MXPA05003665A (es) 2005-06-08
CN1703222A (zh) 2005-11-30
ES2297233T3 (es) 2008-05-01
WO2004032934A1 (en) 2004-04-22
NO20051664L (no) 2005-05-31
RU2005114505A (ru) 2005-10-27
BR0314541A (pt) 2005-07-26
ATE380551T1 (de) 2007-12-15
NZ539329A (en) 2007-11-30
EP1549314A1 (en) 2005-07-06
CA2501348A1 (en) 2004-04-22
HK1080408B (en) 2008-08-08
HK1080408A1 (en) 2006-04-28
AU2003279874A1 (en) 2004-05-04
ZA200502745B (en) 2006-07-26
PL376347A1 (en) 2005-12-27
AU2010200730A1 (en) 2010-03-18
DE60318081T2 (de) 2008-11-06
JP2006504741A (ja) 2006-02-09
RU2332218C2 (ru) 2008-08-27
DE60318081D1 (de) 2008-01-24
US20040116436A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
US9655882B2 (en) Compositions and methods for treatment of neurodegenerative disease
AU2009238370B2 (en) Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration
Russo et al. Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
TW200410672A (en) NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
AU2010200730A1 (en) Method of using (2-imidazolin-2-ylamino) quinoxalines in the treatment of dementia and parkinsons
CA2559221A1 (en) Methods for the treatment of synucleinopathies
US20020102597A1 (en) Methods for selecting compounds for treating ischemia-related cellular damage
US10537567B2 (en) Kinase inhibitors for treatment of disease
AU2011239265A1 (en) Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration
WO2006059423A1 (ja) 過興奮性の細胞傷害によって生じる疾患を治療するための薬剤および方法
KR20200086563A (ko) 산화적 스트레스로부터 성상세포를 보호하는 조성물
Abe et al. The effects of monobromobimane on calcium and phenylarsineoxide-induced mitochondrial swelling and cytochrome C release in isolated brain mitochondria
HK1081880B (en) Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050408

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080725

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100625

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100625

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I